Cantargia AB (publ) (CANTA.ST) fair value

ACCE thesis

Cantargia is a Swedish clinical-stage oncology company developing nadunolimab, an antibody that targets IL1RAP, a protein implicated in tumour growth and treatment resistance, with lead programmes in pancreatic and lung cancers. It has essentially no revenue, so the reported 0.0% growth, 100% gross margin and extreme operating margin reflect a tiny, pre-commercial top line rather than a functioning business, and the P/E of 2.0 and 113.5% ROE should be treated as artefacts of that rather than signs of value. The investment case rests entirely on clinical data: readouts from the nadunolimab trials in combination with chemotherapy would determine whether the asset justifies its roughly 339M SEK market capitalisation. The point to resolve first is the timing and size of those readouts and whether the company is funded through them, since a cash-consuming pipeline at this stage carries dilution risk. A deeper look is warranted only if the trial calendar and cash runway are clear enough to frame binary outcomes.